Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270191 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL2909042 | 0.79 | HDAC6 (0.44) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL3291053 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL4275814 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL3291176 | 0.75 | ADORA2A (0.47) | ALDH1A1 | |
| SCHEMBL27595154 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL14138147 | 0.73 | HDAC6 (0.46) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL383843 | 0.71 | KDM4E (0.40) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL27595155 | 0.71 | KDM4E (0.43) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL2914357 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | KDM4E 3932/4885ALDH1A1 1512/4885HPGD 1350/4885 |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | KDM4E 4056/4885ALDH1A1 2937/4885HPGD 2107/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | KDM4E 4056/4885ALDH1A1 2937/4885HPGD 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.